Become a Kingdom Advisor. Experience world-class training and set yourself apart from your peers. Kingdom Advisors are men and women becoming specialists in offering biblically wise financial advice. Join today to begin your journey to integrate faith and finance.
|I’m a member.||Login to my Account|
|I’d like to join.||Join as a Member|
|I’m just visiting.||Back to Resources|
There are essentially only three reasons people object to BRI: 1) They don’t believe they’re morally responsible for the actions of the companies in their portfolios, 2) They don’t believe their investment dollars make an appreciable difference in the world, and/or 3) They believe BRI will cause them to underperform. This session examines the validity of each of these objections head-on. This session is presented by Finny Kuruvilla, MD, PhD, the Harvard-educated lead portfolio manager for the Eventide Gilead Fund, a Morningstar Five-Star fund.
Finny Kuruvilla is chief investment officer for Eventide Funds, lead portfolio manager on the Eventide Gilead Fund, and portfolio manager on the Eventide Healthcare & Life Sciences Fund.
Dr. Kuruvilla has a unique background in healthcare, statistics, and investing. Concurrent with Eventide, from 2008 through 2016, he was a principal at Clarus Ventures, a leading healthcare and life sciences venture capital firm. Prior to joining Eventide, from 2006-2008, he was a research fellow at the Broad Institute of Harvard and MIT, and from 2005-2008, Dr. Kuruvilla was a clinical fellow at the Brigham and Women’s Hospital and Children’s Hospital Boston and a postdoctoral scientist at MIT.
He holds an MD from Harvard Medical School, a PhD in chemistry and chemical biology from Harvard University, a master’s degree in electrical engineering and computer science from MIT, and a bachelor’s degree from Caltech in Chemistry. Finny and his wife, Laura, have seven children and live in the Boston, Massachusetts area.